Injectable weight-loss drugs outpace pills in India
Injectable weight-loss drugs are quickly outpacing pills like Rybelsus among Indian consumers.
Sales of Rybelsus, an oral medication launched in 2022, have dropped sharply—from 1.46 lakh units last November to just 97,000 this October—while injectables like Eli Lilly's Mounjaro have soared, pulling in ₹450 crore in sales over just seven months.
Experts say buzz around new higher-dose oral versions could help
People see injectables as more effective and easier to use than pills.
While Rybelsus still helps with diabetes and can lead to 3-7% weight loss, its benefits tend to level off, pushing many to try stronger injectable options.
There's also buzz around new higher-dose oral versions (pending US FDA approval) that could help people lose even more weight—possibly bringing some attention back to pills down the line.